Leads Biolabs Advances Opamtistomig Phase II ESCC Study
NANJING, China — August 25, 2026 Leads Biolabs announced that its proprietary Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has...
Opamtistomig
Advertisement
Leads Biolabs Advances LBL-024 Data in First-Line NSCLC
NANJING, China, August 20, 2026 Leads Biolabs announced that the full abstract for its Phase II study of LBL-024...
Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
Leads Biolabs Completes Opamtistomig Phase II Enrollment in BTC
NANJING, China, July 30, 2026 Leads Biolabs announced that its Phase II clinical trial evaluating Opamtistomig (LBL-024), a proprietary...
Leads Biolabs Secures Six ESMO 2026 Research Presentations
NANJING, China, July 13, 2026 Leads Biolabs has strengthened its position in global cancer immunotherapy after announcing that six...
Advertisements
Leads Biolabs Secures Priority Review for Opamtistomig
NANJING, China | July 10, 2026 Nanjing Leads Biolabs Co., Ltd. has announced that the Center for Drug Evaluation...
Leads Biolabs’ Opamtistomig Shows Strong NSCLC Response Ahead of WCLC 2026
NANJING, China, May 28, 2026 Nanjing-based Leads Biolabs announced that updated Phase II clinical data for its proprietary PD-L1/4-1BB...
Leads Biolabs Wins Phase III Approval for Opamtistomig in Advanced EP-NEC
NANJING, China, May 18, 2026 Leads Biolabs announced that its proprietary PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) has received approval...
Advertisement
